Similar Items

Cover Image

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail

Background The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiova...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Dagenais, Gilles R., Rydén, Lars, Leiter, Lawrence A., Lakshmanan, Mark, Dyal, Leanne, Probstfield, Jeffrey L., Atisso, Charles Messan, Shaw, Jonathan E., Conget, Ignacio, Cushman, William C., Lopez-Jaramillo, Patricio, Lanas, Fernando, Cordona Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Basile, Jan, Sheu, Wayne H. H., Temelkova-Kurktschiev, Theodora, Raubenheimer, Peter J., Keltai, Matyas, Hall, Stephanie, Pais, Prem, Colhoun, Helen M., Riddle, Matthew C., Gerstein, Hertzel C., Everest
Format: Artículo de revista
Language:English
Published: Cardiovascular Diabetology 2020-11-01
Online Access:https://repositorio.udes.edu.co/handle/001/6024
Tags: Add Tag
No Tags, Be the first to tag this record!